ABSTRACT
This chapter presents a trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, and clinically significant drug interaction of Protriptyline. If protriptyline pharmacotherapy is required, advise patients of potential benefits and possible risks to themselves and the embryo, fetus, or neonate. Collaboration with the patient’s obstetrician is indicated. Safety and efficacy of protriptyline pharmacotherapy for children have not been established. Protriptyline pharmacotherapy is not recommended for this age group. The rapid onset of action associated with protriptyline pharmacotherapy is clinically useful for patients who are suicidal. It also is useful for patients who require ECT, which can be initiated concurrently with protriptyline pharmacotherapy. Maintenance protriptyline pharmacotherapy should be continued for at least three months following improvement in the signs and symptoms of depression.
